Dr. Westbrook on Combatting Tumor Heterogeneity in HER2+ Breast Cancer

Video

Kelly E. Westbrook, MD, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.

Kelly E. Westbrook, MD, assistant professor, Duke University School of Medicine, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.

Ado-trastuzumab emtansine (T-DM1; Kadcyla) is one antibody-drug conjugate currently in clinical trials with a high affinity for the HER2 receptor that treats HER2-positive cells with minimal toxicity because of low levels of T-DM1 systemically, explains Westbrook. However, it does not have the ability to target patients with low expression of HER2 cells, says Westbrook.

There are many interesting transitions in the antibody-drug conjugate world, including trying to create antibody-drug conjugates that will have an affinity for low levels of HER2 cells or a bystander effect, according to Westbrook. Traditional therapy is not affected by tumor heterogeneity because most HER2-targeted therapies are coupled with a chemotherapy backbone, which helps navigate the tumor heterogeneity, concludes Westbrook.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD